METHODOLOGY: Sprague-Dawley rats were divided into 5 groups of 33 each. Group 1 was administered intravitreally with PBS and group 2 was similarly injected with NMDA (160 nmol). Groups 3, 4 and 5 were injected with TAU (320 nmol) 24 hours before (pre-treatment), in combination (co-treatment) and 24 hours after (post-treatment) NMDA exposure respectively. Seven days after injection, rats were sacrificed; eyes were enucleated, fixed and processed for morphometric analysis, TUNEL and caspase-3 staining. Optic nerve morphology assessment was done using toluidine blue staining. The estimation of BDNF, pro/anti-apoptotic factors (Bax/Bcl-2) and caspase-3 activity in retina was done using ELISA technique.
RESULTS: Severe degenerative changes were observed in retinae after intravitreal NMDA exposure. The retinal morphology in the TAU pre-treated group appeared more similar to the control retinae and demonstrated a higher number of nuclei than the NMDA group both per 100 μm length (by 1.5-fold, p
METHODS: In this work, we present a bit-plane slicing (BPS) and local binary pattern (LBP) based novel approach for glaucoma diagnosis. Firstly, our approach separates the red (R), green (G), and blue (B) channels from the input color fundus image and splits the channels into bit planes. Secondly, we extract LBP based statistical features from each of the bit planes of the individual channels. Thirdly, these features from the individual channels are fed separately to three different support vector machines (SVMs) for classification. Finally, the decisions from the individual SVMs are fused at the decision level to classify the input fundus image into normal or glaucoma class.
RESULTS: Our experimental results suggest that the proposed approach is effective in discriminating normal and glaucoma cases with an accuracy of 99.30% using 10-fold cross validation.
CONCLUSIONS: The developed system is ready to be tested on large and diverse databases and can assist the ophthalmologists in their daily screening to confirm their diagnosis, thereby increasing accuracy of diagnosis.
METHODS: Analyses were conducted post hoc of this 24-month, phase III, double-blind study, in which RRMS patients were randomized (1:1:1) to once daily oral fingolimod 0.5 mg, 1.25 mg or placebo. The key outcomes were the association between baseline RNFLT and baseline clinical characteristics and clinical/imaging outcomes up to 24 months. Change of RNFLT with fingolimod versus placebo within 24 months and time to retinal nerve fiber layer (RNFL) thinning were evaluated.
RESULTS: Altogether 885 patients were included. At baseline, lower RNFLT was correlated with higher Expanded Disability Status Scale score (r = -1.085, p = 0.018), lower brain volume (r = 0.025, p = 0.006) and deep gray matter volume (r = 0.731, p